T ranscatheter aortic valve replacement (TAVR) has rapidly emerged as a highly beneficial treatment for patients with severe aortic stenosis (AS) who are not suitable for surgical aortic valve replacement (SAVR) (1, 2) , or as a less invasive approach to valve replacement for patients at high risk for surgery (3, 4) . Previous studies, primarily using data from a randomized trial of a balloon-expandable TAVR system, have suggested that the clinical benefits of TAVR in nonsurgical candidates are obtained with reasonable incremental costs for most health care systems in North America and Europe (5, 6) . There is less of a consensus, however, on the cost-effectiveness of TAVR relative to surgery (7, 8) .
Recently, the CoreValve U.S. High Risk Pivotal Trial reported a significant reduction in 2-year mortality with TAVR using a self-expanding prosthesis (CoreValve, Medtronic, Minneapolis, Minnesota) compared with SAVR in AS patients at high risk for surgical complications (9) . Given that previous health economic assessments of TAVR have been derived from a somewhat different patient population that was treated with a different TAVR system, questions regarding the costs and benefits of TAVR relative to SAVR in this new context remain pertinent. The aim of the current study was, therefore, to assess the costeffectiveness of TAVR using the self-expandable valve system compared with SAVR in high-risk patients.
METHODS
STUDY DESIGN AND PATIENT POPULATION. As previously reported, the CoreValve U.S. High Risk Pivotal Trial enrolled a total of 795 patients with severe, symptomatic AS who were considered to be at high risk for conventional SAVR. AS was defined as an aortic valve area #0.8 cm 2 or an aortic valve index #0.5 cm 2 /m 2 and either a mean aortic valve gradient >40 mm Hg or a peak jet velocity >4.0 m/s.
All patients were required to have a predicted risk of 30-day mortality $15% on the basis of a combination of the Society of Thoracic Surgery risk score and additional, pre-specified factors not included in the risk score (4, 10) .
Before randomization, all patients were evaluated for anatomic suitability for an iliofemoral (IF) approach using computed tomography angiography.
Those patients who were suitable for an IF approach were randomized to IF-TAVR versus SAVR (n ¼ 663), whereas those patients who were not suitable for an IF approach were randomized to TAVR via a non-IF approach, either via the subclavian artery or direct aortic access, versus SAVR (n ¼ 132).
ANALYTIC OVERVIEW. We evaluated the costeffectiveness of TAVR using the CoreValve system compared with SAVR from the perspective of the U.S. Lifesciences. Dr. Reardon has received honoraria from Medtronic for participation on a surgical advisory board. Dr. Adams has received royalties through his institution from Medtronic for a patent related to a triscupid-valve annuloplasty ring and from
Edwards Lifesciences for a patent related to degenerative valvular disease-specific annuloplasty rings; and is the national co- admissions between $1,000 and $10,000.
RESULTS
As previously reported, of the 795 patients enrolled in the CoreValve U.S. High Risk Pivotal Trial, a total of 390 underwent attempted TAVR and 357 underwent attempted SAVR and constituted the primary analytic population for our study (4) . These patients had a mean age of 83 years, were almost evenly divided between men and women, and had a high burden of comorbid health problems, with mean STS-predicted risk of mortality scores >7 (Online Table 1 ). There were no important differences in baseline clinical or echocardiographic characteristics between the TAVR and SAVR groups. with respect to health care resource utilization or costs during the 12-month follow-up period ( Table 2) .
Mainly due to a small and not statistically significant difference in residential care costs, total follow-up costs tended to be slightly lower in the TAVR pa- Abbreviations as in Table 1 . Table 3 ). Projected quality-adjusted survival was w20% lower in both groups, and with discounting, the mean difference between groups was 0.32 QALY (95% CI: -0.02 to 0.69) ( Table 3) .
Given the high background medical costs of the patient population, the TAVR group, by virtue of its longer predicted survival, accrued additional longterm incremental health care costs in our analysis. Table 3) .
S u b g r o u p a n d s e n s i t i v i t y a n a l y s e s . Lifetime costs, effectiveness, and cost-effectiveness within key subgroups and from major sensitivity analyses are shown in In sensitivity analyses, the ICER was not sensitive to variations in the discount rate, to lowering the long-term HR from its assumed value of 1.0 to the observed value of 0.86, or to the exclusion of costs accrued during added years of life ( Table 3 ). Figure 1 illustrates the potential impact of lowering the costs of index TAVR admissions compared with costs for the base case. Each $1,000 reduction in the index TAVR admission cost was found to lower the ICER by w$3,000 per QALY. As a result, even a modest reduction of w$1,650 in the cost of the index hospitalization for TAVR was projected to lead to an ICER below $50,000/QALY gained. Mean incremental 12-month costs and benefits (TAVR -SAVR) are plotted on the cost-effectiveness plane with benefits expressed as QALY (A) or LY (B). Solid circles represent base case estimates, the surrounding open circles represent individual results for 1,000 replications of the study using bootstrap resampling, and the lines represent a willingness to pay threshold of $50,000 per QALY/LY gained (green) or $150,000 per QALY/LY gained (purple).
For both effectiveness outcomes, the point estimates are near $50,000 per QALY/LY gained and w90% of replicates are below $150,000 per QALY/LY gained. See text and As expected, we found that procedural costs were substantially higher with TAVR than with SAVR, and that those costs were offset by savings from shortened hospital length of stay and a reduced need for post-discharge residential care. In this trial, those offsets were not sufficient for TAVR to achieve overall cost neutrality relative to SAVR, either in the short or long term. The conclusion that TAVR is nonetheless a reasonable value consequently hinges on the observed clinical benefits. These findings have important implications, as TAVR is evaluated in lowerrisk AS patients. At current valve prices, length of stay would likely need to be at least 5 to 6 days shorter with TAVR than with SAVR in order to approach cost neutrality.
There were a few notable variations in estimated cost-effectiveness across key subgroups of interest.
As seen previously (7) There were also possible differences in costeffectiveness outcomes on the basis of sex, driven harvard.edu.
